Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt
NCT ID: NCT04488588
Last Updated: 2020-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1064 participants
OBSERVATIONAL
2020-03-15
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Initially described in China in December 2019, severe acute respiratory syndrome caused by corona virus 2 (SARS-CoV-2) has spread all over the world and by 18th July 2020- there was an emergent figure of 13,824,739 confirmed cases and 591.666 losses reported to the WHO. To date, Egypt reported slightly over 82,000 confirmed COVID-19 cases with 3858 deaths. The new pandemic is injuring not only health organizations of several countries but also the financial prudence universal.
Defining the clinical features and associated outcomes of patients diagnosed with coronavirus disease (COVID-19) is fundamental to improving our understanding and adequate management of this illness. Several articles have recently been published, describing the clinical features and outcomes of retrospective individuals with COVID-19
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)
NCT04443712
Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients
NCT04584606
Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment
NCT04530422
A Simple Approach to Prevent Hospitalization for COVID-19 Patients
NCT04854824
Remdesivir Efficacy In Management Of COVID-19 Patients
NCT04853901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Kaplan Meier analysis
Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
36 Years
63 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aliae AR Mohamed Hussein
Professor of Pulmonology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aliae Mohamed-Hussein, MD
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AssiutU
Asyut, , Egypt
Aliae Mohamed-Hussein
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AssiutU17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.